Serotonin (5-hydroxytryptamine, 5-HT) may play an important role in the pathogenesis of schizophrenia. Previous studies suggested that the efficacy of atypical neuroleptic drugs (e.g., risperidone and clozapine) on negative symptoms may be related to the 5-HT2a receptor. Although association studies between Msp I polymorphism (T102C) and the 5-HT2a receptor gene and schizophrenia have been reported, their results are still controversial. The aim of this study was to examine the association between T102C polymorphism of the 5-HT2a receptor gene and schizophrenia as well as the association between the polymorphism and negative symptoms in a Japanese population (106 patients with schizophrenia and 109 healthy controls). No significant positive associations were observed. Our results suggest that the 5-HT2a receptor gene is not involved in the pathogenesis of schizophrenia or negative symptoms.

1.
Meltzer HY, Bastani B, Kwon KY, Ramirez LF, Burnett S, Sharpe J: A prospective study of clozapine in treatment-resistant schizophrenic patients. Psychopharmacology 1989; 99:68–72.
2.
Leysen JE, Janssen PM, Gommeren W, Wynants J, Pauwels PJ, Janssen PA: In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain region of the novel antipsychotic risperidone and ocaperidone. Mol Pharmacol 1992;41:494–508.
3.
Farde L, Nyberg S, Oxenstierna G, Nakashima Y, Halldin C, Ericksson B: Positron emission tomography studies on D2 and 5-HT2 receptor binding in risperidone-treated schizophrenic patients. J Clin Psychopharmacol 1995;15(suppl 1):19S–23S.
4.
Goyer PF, Berridge MS, Semple WE, Morris ED, Wong DF, Schulz SC, Miraldi F, Meltzer HY: Dopamin2 and serotonin2 receptor indices in clozapine treated schizophrenic patients. Schizophr Res 1993;9:199.
5.
Saltzman AG, Morse B, Whitman MM, Ivanshchenko Y, Jaye M, Felder S: Cloning of the human serotonin 5-HT2 and 5-HT1C receptor subtypes. Biochem Biophys Res Commun 1991;181:1469–1478.
6.
Warren JT Jr, Peacock ML, Rodriguez LC, Fink JK: An Msp I polymorphism in the human serotonin receptor gene (HTR2); detection by DGGE and RFLP analysis. Hum Mol Genet 1993;2:338.
7.
Inayama Y, Yoneda H, Ishida T, Nonomura Y, Kono Y, Koh J, Kuroda K, Higashi H, Asaba H, Sakai T: An association between schizophrenia and a serotonin receptor DNA marker (5HTR2). Neuropsychopharmacology 1994;10:56S.
8.
Williams J, McGuffin P, Nothen M, Owen MJ: Meta-analysis of assciation between the 5-HT2a receptor T102C polymorphism and schizophrenia. EMASS Collaborative Group. European Multicentre Association Study of Schizophrenia. Lancet 1997;349:1221.
9.
Ishigaki T, Xie DW, Liu JC, Nakamura Y, Zhang HY, Tani K, Shimazu Y, Chen K, Shih JC, Miyasato K, Ohara K, Ohara K: Intact 5-HT2A receptor exons and the adjoining intron regions in schizophrenia. Neuropsychopharmacology 1996;14:339–347.
10.
Verga M, Macciardi F, Cohen S, Pedrini S, Smeraldi E: No association between schizophrenia and the serotonin receptor 5HTR2a in an Italian population. Am J Med Genet 1997;74:21–25.
11.
Krawiecka M, Goldberg D, Vaughan M: A standardized psychiatric assessment scale for rating chronic psychotic patients. Acta Psychiatr Scand 1977;55:299–308.
12.
Erdmann J, Shimron-Abarbanell D, Rietschel M, Albus M, Maier W, Körner J, Bondy B, Chen K, Shih JC, Knapp M, Propping P, Nöthen MM: Systematic screening for mutations in the human serotonin-2A (5-HT2A) receptor gene: Identification of two naturally occurring receptor variants and association analysis in schizophrenia. Hum Genet 1996;97:614–619.
13.
Smith CA, Smith G, Wolf CR: Genetic polymorphisms in xenobiotic metabolism. Eur J Cancer 1994;30A:1921–1935.
14.
Burnet PW, Harrison PJ: Genetic variation of the 5-HT2A receptor and response to clozapine. Lancet 1995;346:909.
15.
Ohara K, Ino A, Ishigaki T, Tani K, Tsukamoto T, Nakamura Y, Ohara K: Analysis of the 5′-flanking promoter region of the 5-HT2A receptor gene in schizophrenia. Neuropsychopharmacology 1997;17:274–278.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.